



Insulin-induced lipodystrophy in hemodialyzed patients: A new challenge for nephrologists?

S. Gentile ^{a,b,*}, F. Strollo ^{b,c}, E. Satta ^b, T. Della-Corte ^{a,b}, C. Romano ^b,
G. Guarino ^a, on behalf of Nefrocenter Research Study Group: Nephrologists,
Diabetologists, Nurses

^a Campania University “Luigi Vanvitelli”, Naples, Italy

^b Nefrocenter Research Network, Naples, Italy

^c Elle-Di and San Raffaele Research Institute, Rome, Italy

ARTICLE INFO

Article history:

Received 17 July 2019

Accepted 11 November 2019

Keywords:

Hemodialysis

Hypoglycemia

Lipodystrophy

Injection technique

Insulin

ABSTRACT

Diabetes Mellitus (DM) is the most common cause of renal failure and ESRD all over the world, and often requires an individualized insulin treatment regimen. Malnutrition, depression-related eating behavior changes, high on-off-dialysis day-to-day glycemic variability and frequent hypoglycemic events occurring during or immediately after dialysis make it hard to identify best insulin dosage in hemodialyzed patients. This suggests a prudent attitude including non-stringent control, despite which repeated hypoglycemia quite often occurs in such patients. When looking for possible sources of hypoglycemia, health professionals too often overlook the identification of skin lipodystrophy (LD) due to an incorrect insulin injection technique. This mini-review focuses on the high frequency (57%) of LD in a cohort of 1004 insulin-treated people with DM on dialysis consecutively referring to our joint medical centers, and on its relationship with hypoglycemia and glycemic control/variability. When taking on such patients, care team members accept to face a complex disease burdened with several risk factors requiring high professional skills, and have to keep in mind also the possible presence of any LD areas eventually interfering with expected results. A timely educational intervention on the correct injection technique can help reduce the high risk of hypoglycemia and large glycemic variability in dialysed people with DM.

© 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Insulin is necessary for carbohydrate, protein, and fat metabolism. People with diabetes mellitus (DM) either do not produce enough of it to sustain life and therefore depend on exogenous supply for survival - which is the case for type 1 DM (T1DM) - or produce sufficiently high amounts of less active insulin to survive - which is the case for type 2 DM (T2DM) - but over the years, and especially in case of stress or intercurrent illness making insulin secretion insufficient, often require exogenous administration for adequate blood glucose control.

2. Diabetes and end stage renal disease

An insulin regimen is often required in the treatment of several comorbidities, such as end stage renal disease (ESRD). Whenever insulin is needed, its dosage must be individually customized to nutrition and exercise habits. DM is the most common cause of renal failure and ESRD all over the world so that people with ESRD quite often have insulin requiring DM as a result of either severe deficiency or alternative drug contraindications [1].

Various factors make it difficult to establish optimal insulin doses in the hemodialyzed patient, including malnutrition, depression-related eating behavior changes, high on-off-dialysis day-to-day glycemic variability and increased hypoglycemic risk during or immediately after dialysis. For these reasons it is suggested to keep glycemic control within HbA1c values 7.5%–8.5% [2].

* Corresponding author. Campania University “Luigi Vanvitelli”, Naples, Italy.
E-mail address: s.gentile1949@gmail.com (S. Gentile).

3. Insulin and lipohypertrophy

Since insulin commercialization skin lipodystrophy (LD) - predominantly atrophic (LA) - has been described at injection sites [3–6]. Initially its etiology was not understood but we now know they depended on both inner lipo-active insulin properties and on immuno-allergic, inflammatory reactions due to impurities contaminating animal extracts [7,8].

Today the most frequent type of LD is lipo-hypertrophy (LH), which is due to (i) non-compliance to injection site rotation suggestion, (ii) too long and (iii) often reused needles, (iv) especially when repeatedly inserted into the same site within restricted skin areas, and, (v) the utilization of ice-cold insulin [8].

4. Statements and recommendations

Various Expert Forums have been organized so far all over the world to collect evidence from the literature on how to prevent and/or treat LD [9–14].

In addition, for years several Scientific Societies have been issuing consensus statements, and National Expert Groups have been producing recommendations and guidelines on proper injection techniques to prevent LD from resulting into poor metabolic control [15–23]. However, with somewhat different frequency distribution among reports (most likely dependent on discrepancies in identification methods) [24–26], LD occurrence rates still keep higher than 50% and get mostly up to 1/3 cases in insulin-requiring patients world-wide.

5. Real life

Despite excellent results of adequate education [17,27,28], the best frequency of periodic refreshers needed to maintain a correct injection technique over time remains unknown. In addition, the largest difference between clinical practice observations and educational trial results is the direct consequence of unabated LD rate worldwide despite easily available guidelines/recommendations and ever improving high-tech administration devices.

The most relevant consequences of that [8,28] are unpredictable hypoglycemia and large glycemetic variability, both of which depend on either erratic insulin release and absorption from fibrous and edematous areas (in case of LH occurrence) [29] or on unexpectedly high insulin amounts massively entering the blood stream (in case of LA) [30]. In fact LH deteriorates metabolic control and quality of life, thus paving the way to acute and chronic complications and sharply increasing health-related costs [31] as independent factors of increased cardiovascular (CV) risk, all-cause mortality and hospitalization [32].

6. Insulin treatment and ESRD

All patients on hemodialysis are at high risk for CV events and higher mortality rate as a result of the often associated comorbidities including DM, and therefore get even frailer whenever the deleterious metabolic effects of LD happen to further increase CV risk. That's why LD identification and timely refreshers on correct injection techniques are crucial for their survival. In the first observational study specifically oriented to 1004 insulin-treated hemodialyzed patients referring to our joint medical centers, we found as high as 57% LH lesion rates, not dissimilar to those found in insulin-treated DM patients without ESRD [33]. This came with poorer glycemetic control (HbA1c) (Fig. 1) in patients with LHs than those without LHs together with a significantly higher frequency of needle reuse (Fig. 1) and HYPOs (severe/non severe) (Fig. 2), as well as, a wider glycemetic variability (Fig. 3).




Fig. 1. Quantitative independent variables grouped by LH presence (n.169, blue bars)/absence (n.127, red bars), and significant differences in a series of 296 dialysis patient with insulin-treated diabetes out of 1004 dialyzed patients: 1) Age (y) p n.s.; 2) Diabetes Duration (y) p n.s.; 3) Dialysis Duration (y) p n.s.; 4) HbA1c (%) p < 0.007***; 5) Needle reuse (frequency) p < 0.029*.




Fig. 2. Mean rates of severe/non severe hypoglycemia (HYPOs %) in patients without LH (LH-) and with LH (LH+) over three months: p < 0.0001 (***).




Fig. 3. Glycemetic variability (mg/dl), calculated as means of day-to-day variability between days on and off dialysis: p < 0.007 (**).

7. A new challenge for medical teams

Therefore, when taking on patients with diabetes and ESRD needing dialysis, the nephrologist and all his team accept to face a complex disease burdened with several risk factors requiring high professional skills. They must keep in mind all patient's comorbidities and, when trying to dampen glycemetic variations observed among days on and off dialysis or between the time of dialysis and the one immediately before/after dialysis, they must also rule out the presence of any LH areas eventually interfering with expected results.

8. Future perspectives

LH identification represents a new challenge for the nephrologist, who in turn can experience the great satisfaction of significantly improving not only glycemic control, but also the outcome of all comorbidities and the overall prognosis of their DM patients on long-term dialysis.

Authorship

SG and FS laid out the paper plan and wrote the manuscript. ES, TDC and GG critically read the paper. All Collaborators (see the List of Members of the Nefrocenter Research Study Group, Reference n. 33) complied with data collection, critically assessed the results and approved the final text.

Ethical standards

This study was conducted in conformance with good clinical practice standards. The study was led in accordance with the Declaration of Helsinki 1975, as revised in 2008, and was approved by all the Ethics Committees of the Centers participating in the study.

Human and animal rights

All followed procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national).

Informed consent

Written informed consent was obtained from all participants before enrollment.

Declaration of competing interest

The authors declare no conflicts of interest.

Acknowledgements

The paper was supported by a non-conditioning special grant from the Nefrocenter Research Network, Naples, Italy. The authors of this manuscript meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship, take responsibility for the integrity of the work as a whole, and gave final approval for the version to be published. Special thanks are due to Paola Murano and to Members of AMD-OSDI Study Group on Injection Technique, for editorial assistance.

References

- [1] Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45mL/min). *NDT* 2015;30:1284–300. ii1–ii142.
- [2] Frankel AH, Kazempour-Ardebili S, Bedi R, Chowdhury TA, De P, El-Sherbini N, Game F, Gray S, Hardy D, James J, Kong MF, Ramlan G, Southcott E, Winocour P. Management of adults with diabetes on the haemodialysis unit: summary of guidance from the Joint British Diabetes Societies and the Renal Association. *Diabet Med* 2018 Aug;35(8):1018–26. <https://doi.org/10.1111/dme.13676>.
- [3] Williams J. R.: lipoatrophy following the injection of insulin. *Journal of Metabolic Research* 1922;2:729.
- [4] Depisch F. Über lokale lipodystrophie bei lange zeit mit insulin behandelten fallen von diabetes. *Klin Wochenschr* 1926;42.
- [5] Karborka CJ. Fatty atrophy from injections of insulin: report of two cases. *J Am Med Assoc* 1926;87(20):1646–7. <https://doi.org/10.1001/jama.1926.92680200003012c>.
- [6] Absorption of subcutaneous fat deposits at site of repeated insulin injections. Report of case. *Davidson RA. Calif West Med* 1927;26(2):210–2.
- [7] Collens WS, Boas LC, Zilinsky JD, Greenwald JJ. Lipoatrophy following the injection of insulin; a method of control. *N Engl J Med* 1949 Oct 20;241(16):610.
- [8] Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. *Diabetes Metab* 2013;39:445–53.
- [9] Strauss K. Insulin injection techniques: report from the 1st international insulin injection technique workshop. *Pract Diabetes Int* June 1997;1998(15):16–20. Strasbourg, France.
- [10] Strauss K, De Gols H, Letondeur C, Matyjaszczyk M, Frid A. The second injection technique event (SITE). *Pract Diabetes Int* May 2000;2002(19):17–21. Barcelona, Spain.
- [11] Frid A, Hirsch L, Gaspar R, Hicks D, Kreugel G, Liersch J, Letondeur C, Sauvanet JP, Tubiana-Rufi N, Strauss K. The third injection technique workshop in athens (TITAN). *Diabetes Metab* 2010 Sep;2(36):S19–29. [https://doi.org/10.1016/S1262-3636\(10\)70003-3](https://doi.org/10.1016/S1262-3636(10)70003-3).
- [12] The forum for injection techniques (FIT) 2014, Canada-English • Canada-français- Switzerland - United Kingdom • Ireland • India – South Africa – rest of the world. <http://fit4diabetes.com/>. in April 2019.
- [13] The forum for injection techniques (FIT) 2014, Canada-English • Canada-français- Switzerland - United Kingdom • Ireland • India – South Africa – rest of the world. <http://fit4diabetes.com/>. in April 2019.
- [14] Frid AH, Hirsch LJ, Menchior AR, et al. Worldwide Injection Technique Questionnaire study: population parameters and injection practices. *Mayo Clin Proc* 2016;91:1212–23.
- [15] American Diabetes Association. Insulin administration. Position statement. *Diabetes Care* 2001 Nov;24(11):1984–7. <https://doi.org/10.2337/diacare.24.11.1984>.
- [16] Ji L, Li Q, Wei G. Lipohypertrophy—prevalence, risk factors and clinical characteristics of insulin-requiring patients in China. *Diabetes Technol Ther* 2017;19:61–7.
- [17] Smith M, Clapham L, Strauss K. UK lipohypertrophy interventional study. *Diabetes Res Clin Pract* 2017;126:248–53.
- [18] Dagdelen S, Deyneli O, Olgun N, Siva ZO, Sargin M, Hatun S, Kulaksizoglu M, Kaya A, Gürele CA, Hirsch LJ, Strauss KW. ITQ Turkish study Group. Turkish insulin injection technique study: population characteristics of Turkish patients with diabetes who inject insulin and details of their injection practices as assessed by survey questionnaire. *Diabetes Ther* 2018 Aug;9(4):1629–45. <https://doi.org/10.1007/s13300-018-0464-7>. Epub 2018 Jun 30.
- [19] Tsadik AG, Atey TM, Nedi T, Fantahun B, Feyissa M. Lipodystrophy on glycemic control among Children and adolescents with diabetes in tikur anbesa specialized hospital, addis ababa, Ethiopia. 2018;4910962 *J Diabetes Res* 2018 Jul 4. <https://doi.org/10.1155/2018/4910962>. eCollection 2018.
- [20] Tandon N, Kalra S, Balhara YPS, Baruah MP, Chadha M, Chandalia HB, Prasanna Kumar KM, Madhu SV, Mithal A, Sahay R, Shukla R, Sundaram A, Unnikrishnan AG, Saboo B, Gupta V, Chowdhury S, Kesavadev J, Wangnoo SK. Forum for injection technique and therapy Expert recommendations, India: the Indian recommendations for best practice in insulin injection technique, 2017. *Indian J Endocrinol Metab* 2017 Jul-Aug;21(4):600–17. https://doi.org/10.4103/ijem.IJEM_97_17 [Review].
- [21] Tandon N, Kalra S, Balhara YP, Baruah MP, Chadha M, Chandalia HB, Chowdhury S, Jothevdev K, Kumar P V, M S, Mithal A, Modi S, Pitale S, Sahay R, Shukla R, Sundaram A, Unnikrishnan AG, Wangnoo SK. Forum for injection technique (FIT), India: the Indian recommendations 2.0, for best practice in insulin injection technique, 2015. *Indian J Endocrinol Metab* 2015 May-Jun;19(3):317–31. <https://doi.org/10.4103/2230-8210.152762>.
- [22] Gentile S, Strollo F, De Rosa N, Grassi G, Lalli C, Lo Grasso G, A Ma Marcone T, Sudano M, Gentile L, Giancaterini A, Tatti P, Tonutti L, Armentano V, Chiandetti R, Garrapa G, De Riu S, Cucco L, Speese K, Botta A. Injection-related local side effects in the treatment of diabetes mellitus: a methodological approach and possible solutions. Consensus statement of AMD-OSDI study Group on injection technique. In: SM Group open access eBooks “diabetes complications” of creative commons attribution; 2016. Dover, DE 19904, USA, <https://smjournals.com/ebooks/diabetic-complications/index.php>.
- [23] Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch LJ, Smith MJ, Wellhoener R, Bode BW, Hirsch IB, Kalra S, Ji L12, Strauss KW. New insulin delivery recommendations. *Mayo Clin Proc* 2016;91(9):1231e55. <https://doi.org/10.1016/j.mayocp.2016.06.010>.
- [24] Gentile S, Guarino G, Guida P, Strollo F. On behalf of the AMD-OSDI Italian Injection Technique Study Group. A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. *SpringerPlus* 2016;5:563. <https://doi.org/10.1186/s40064-016-1978-y>.
- [25] Gentile S, Strollo F, Guarino G. Why are so huge differences reported in the occurrence rate of skin lipohypertrophy? Does it depend on method defects or on lack of interest? *Diabetes, Metab Syndrome* 2019 Jan - Feb;13(1):682–6. <https://doi.org/10.1016/j.dsx.2018.11.042>. Epub 2018 Nov 16.
- [26] Deng N, Zhang X, Zhao F, Wang Y, He H. Prevalence of lipohypertrophy in insulin-treated diabetes patients: a systematic review and meta-analysis. *J Diabetes Investig* 2017 Sep 1. <https://doi.org/10.1111/jdi.12742> [Epub ahead of print].
- [27] Saez-de Ibarra L, Gallego F: factors related to lipohypertrophy in insulin-treated diabetic patients; role of educational intervention. *Pract Diabetes Int* 1998;15:9–11.
- [28] Campinos C, Le Floch JP, Petit C, Penfornis A, Winiszewski P, Bordier L, Lepage M, Fermon C, Louis J, Almain C, Morel D, Hirsch L, Strauss KW. An

- effective intervention for diabetic lipohypertrophy: results of a randomized, controlled, Prospective multicenter study in France. *Diabetes Technol Ther* 2017 Nov;19(11):623–32. <https://doi.org/10.1089/dia.2017.0165>. Epub 2017 Oct 23.
- [29] Bertuzzi F, Meneghini E, Bruschi E, Luzi L, Nichelatti M, Epis O. Ultrasound characterization of insulin induced lipohypertrophy in type 1 diabetes mellitus. *J Endocrinol Investig* 2017 Oct;40(10):1107–13. <https://doi.org/10.1007/s40618-017-0675-1>. Epub 2017 Apr 27.
- [30] Hirsch L, Byron K, Gibney M. Intramuscular risk at insulin injection sites-measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. *Diabetes Technol Ther* 2014;16:867–73.
- [31] Gentile S, Strollo F, Nefrocenter Research Study Group. Cost saving effects of a short-term educational intervention entailing lower hypoglycaemic event rates in people with type 1 diabetes and lipo-hypertrophy. *Diabetes Res Clin Pract* 2018 Sep;143:320–1. <https://doi.org/10.1016/j.diabres.2018.07.030>. Epub 2018 Aug 1.
- [32] Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. *Lancet Diabetes Endocrinol* 2019 Mar;7(3):221–30. [https://doi.org/10.1016/S2213-8587\(18\)30136-0](https://doi.org/10.1016/S2213-8587(18)30136-0). Epub 2018 Aug 13.
- [33] Gentile S, Strollo F, Satta E, Della-Corte T, Romano C, Guarino on behalf of Nefrocenter Research Study Group: nephrologists, Diabetologists, Nurses. Insulin-related lipohypertrophy in dialyzed diabetic patients: an observational multicenter study and a methodological approach. *Diabetes Ther* 2019 Aug;10(4):1423–33. <https://doi.org/10.1007/s13300-019-0650-2>. Epub 2019 Jun 20.